Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer

HER2DX reflects key biological and pathologic features of HER2+ breast cancer and independently predicts pCR, supporting its utility for individualized treatment decision-making.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2025-12-01
DOI
https://doi.org/10.1158/1078-0432.ccr-25-3123
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer

Pedro Jares, Fara Brasó‐Maristany, Juan Miguel Cejalvo, Sandra Cobo et al.
Clinical Cancer Research
HER2/EGFR in Cancer Research
article

Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer

Pedro Jares, Fara Brasó‐Maristany, Juan Miguel Cejalvo, Sandra Cobo, R Gómez-Bravo, Marta Tapia, Blanca González‐Farré, Rodrigo Sánchez-Bayona, Jesús Soberino, Anabel Martínez-Romero, Francisco J. Pardo-Palacios, Eva Hernández‐Illán, Javier Cortés, Joel S. Parker, Olga Martínez‐Sáez, Cristina Tebar, Esther Sanfeliu, Laia Paré, Kepa Amillano, Santiago Escrivá-de-Romaní, Eva Ciruelos, Patricia Villagrasa, Cristina Saura, Wesley Buckingham, Mercedes Marín‐Aguilera, Serafin M. Morales, Montserrat Muñoz-Mateu, Aleix Prat, Joan Anton Puig‐Butillé
article en

Abstract

HER2DX reflects key biological and pathologic features of HER2+ breast cancer and independently predicts pCR, supporting its utility for individualized treatment decision-making.

Clinical Cancer ResearchVol. 32(3)
University of North Carolina at Chapel Hill (US), Breast Cancer Research Foundation (US), Hospital Universitari Arnau de Vilanova (ES), Research Institute Hospital 12 de Octubre (ES), Hospital Clínico Universitario de Valencia (ES), Hospital Universitario 12 De Octubre (ES), Vall d'Hebron Institut de Recerca (ES), Fomento de Construcciones y Contratas (Spain) (ES), Hospital Quirónsalud Barcelona (ES), Hospital Clínic de Barcelona (ES), Hospital Arnau de Vilanova (ES), Genomics Medicine (Ireland) (IE), Solti (ES), Oryzon Genomics (Spain) (ES), Hospital Universitari Sant Joan de Reus (ES), Fundació Clínic per a la Recerca Biomèdica (ES), INCLIVA Health Research Institute (ES), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), Vall d'Hebron Institute of Oncology (ES), Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer (ES), Universitat de Barcelona (ES)
Breast Cancer Research Foundation, European Commission, Fundación Científica Asociación Española Contra el Cáncer, Fundación Fero, Instituto de Salud Carlos III
Openalex Percentile: Top 48%
HER2/EGFR in Cancer Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.